The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 24 February 2004, www.theannals.com, DOI 10.1345/aph.1D296.
 The Annals of Pharmacotherapy: Vol. 38, No. 4, pp. 700-704. DOI 10.1345/aph.1D296
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sandhu, G. K
Right arrow Articles by Heyneman, C. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sandhu, G. K
Right arrow Articles by Heyneman, C. A

DRUG INFORMATION ROUNDS

OBJETIVO: Determinar el potencial de nefrotoxicidad relativo de los inhibidores de la COX-2.

FUENTES DE INFORMACIÓN: Se identificaron pruebas clínicas que evaluaron la nefrotoxicidad de los inhibidores de la COX-2 contra los AINE tradicionales mediante una búsqueda en MEDLINE (1966–junio 2003). Los términos clave de búsqueda incluyeron inhibidores de la ciclooxigenasa, agentes antiinflamatorios no esteroidales, nefrotoxicidad, e inducido químicamente.

SÍNTESIS: Los datos de los resultados obtenidos de los pocos estudios publicados son equívocos. Existen varias limitaciones de metodología.

CONCLUSIONES: Los inhibidores de la COX-2 puede que no ofrezcan ventajas distintas de los AINE no selectivos con respecto a la función renal. Se requieren pruebas de mayor duración en pacientes que tengan comorbilidades. Estos agentes deben usarse con cautela o no utilizarse en pacientes con condiciones que predispongan al paciente a sufrir algún daño.

www.theannals.com, DOI 10.1345/aph.1D296


This article has been cited by other articles:


Home page
 JAMAHome page
J. Zhang, E. L. Ding, and Y. Song
Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials
JAMA, October 4, 2006; 296(13): 1619 - 1632.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
R. C. Harris and M. D. Breyer
Update on Cyclooxygenase-2 Inhibitors
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 236 - 245.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sandhu, G. K
Right arrow Articles by Heyneman, C. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sandhu, G. K
Right arrow Articles by Heyneman, C. A

homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.